Skip to main content
. 2018 Sep 12;13:176–188. doi: 10.1016/j.omtn.2018.08.014

Figure 4.

Figure 4

MLN8237 Inhibits Activities of p-Akt and p-p38 MAPK in HepG2 and SMMC-7721 Cells

(A and B) HepG2 (A) and SMMC-7721 (B) cells were treated with sorafenib, MLN8237, or both for 48 hr. Western blotting was then conducted to monitor the expression of p-Akt, total Akt, p-p38 MAPK, and total p38-MAPK in the cells. (C and D) HepG2 cells treated with sorafenib, MLN8237, or both for 48 hr. Immunofluorescence to determine the expression of p-Akt (C) and p-p38 MAPK (D) in HepG2 cell.